Enzymatic Wound Debridement Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Enzymatic Wound Debridement Market Analysis
The enzymatic wound debridement market is projected to grow with a CAGR of nearly 5.3% over the forecast period.
The COVID-19 outbreak impacted the enzymatic wound debridement market and the overall healthcare sector during the initial phases, as hospitals and healthcare services were reduced due to social distancing measures taken by governments worldwide. According to an article in September 2021 by the American Journal of Managed Care, during COVID-19, a large number of patients with chronic wounds delayed preventative and urgent wound care due to the lockdown. Such delays profoundly impacted the market's growth. During the pandemic, wound care was prioritized to avoid significant wound complications by reducing hospitalization and surgery. The reduction in the available wound care management services during the COVID-19 pandemic impacted the market growth. However, the sector has been recovering well since restrictions were lifted. An increase in wound care product sales, new product launches, and increasing demand for a faster cure for chronic wounds leading the market recovery over the last two years.
The major factors attributing to the growth of the market include the increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases. For instance, according to the IDF Diabetes Atlas 10th edition 2021, an estimated 537 million adults live with diabetes worldwide. This number is predicted to rise to 643 million by 2030 and 783 million by 2045. The risk of foot ulcers increases with uncontrolled diabetes. The rising cases of diabetic people indicate a higher risk for the rising number of chronic wounds such as diabetic foot ulcers, which is augmenting the growth of the market studied. Moreover, as per Mission Regional Medical Center 2022 update, it is estimated that 6.7 million people currently live with chronic wounds, and that number is expected to grow by more than 2% for the next decade. Chronic wounds cost the healthcare system more than USD 50 billion each year. In the United States, more than 29 million people (9.5% of the population) have diabetes, and nearly two million of those people are likely to develop a diabetic foot ulcer or another non-healing wound each year. Hence considering the advantages of enzymatic wound debridement, the market is anticipated to witness growth over the forecast period.
Furthermore, product launches, mergers, and acquisitions in the field of enzymatic wound debridement are anticipated to boost market growth over the forecast period. For instance, in August 2022, 3M Health Care's Medical Solutions Division introduced a new 3M Veraflo Cleanse Choice Complete Dressing Kit and a software upgrade for the 3M V.A.C. These new products assisted the doctors employing Veraflo Therapy (negative pressure wound therapy with instillation) in simplifying care delivery processes and making wound dressing changes easier, faster, and less stressful for their patients when compared to previous Veraflo Therapy dressings.
Hence, due to the increase in the incidence of chronic diseases like diabetes, the rise in the number of accidents, and technological advancements in enzymatic wound debridement products, the enzymatic wound debridement market is anticipated to witness growth over the forecast period. However, stringent regulatory policies are likely to restrain the market growth over the forecast period.
Enzymatic Wound Debridement Market Trends
This section covers the major market trends shaping the Enzymatic Wound Debridement Market according to our research experts:
Collagenase-Based Enzymatic Wound Debridement Products are Expected to Witness Rapid Growth in the Market Over the Forecast Period
Collagenase-based enzymatic wound debridement products are predominantly used for healing surgical wounds. Most surgical wounds after cancer surgery are relatively large and deep, which generates exudate that needs regular supervision. Thus, the proper use of these products helps handle large wounds, which substantially reduces the risk of infection. Therefore, the rising incidence of chronic diseases is anticipated to increase the demand for enzymatic wound debridement products, thereby propelling market growth over the forecast period. According to the study titled published in Diabetes Research and Clinical Practice in February 2021, in Germany, the cumulative diabetic foot ulcer recurrence rate was around 70% over a 15-year period, and patients who have had an ulcer before are more likely to experience another one in the future. Thus, an increased recurrence rate of DFU is expected to boost segment growth over the forecast period.
Moreover, several studies have focused on the use of collagenase-based enzymatic wound debridement products in chronic wound healing. For instance, an article titled published in January 2022 by PubMed indicated that the combined action of hyaluronic acid and collagenase ointment demonstrated a reduction in healing time while improving healing quality, with a decrease in pain. Such studies are expected to boost market growth over the forecast period. Furthermore, an increasing number of accidents, such as road accidents, burns, and trauma, across the world is also projected to propel growth. For instance, as per the French Road Safety Observatory 2022 update, the number of injury accidents recorded by police forces was 3,728 in January 2022, higher than last year's result (3,508 accidents). Further, as per the Government of UK 2021 update, 11,194 cases were reported for shallow cuts, lacerations/abrasions in the road casualties that occurred in 2021. As per the same source, 524 cases of severe head injury, 968 cases of deep cuts/lacerations, and 276 cases of severe chest injury were reported. As accidents and injuries are increased the chance of using collagenase-based enzymatic wound debridement products is also raised which is likely to boost the market growth.
Hence, due to the rise in chronic wounds, the number of accidents, and technological advancements in the products, the collagenase-based enzymatic wound debridement product segment is likely to witness growth in the market over the forecast period.
Understand The Key Trends Shaping This Market
North America is Expected to Grow the Enzymatic Wound Debridement Market Over the Forecast Period
North America is expected to witness growth in the overall market, throughout the forecast period owing to the factors such as the presence of key players, the high prevalence of chronic diseases and accidents in the region, and the established healthcare infrastructure. For instance, according to the IDF Diabetes Atlas Tenth edition, in 2021, around 32.2 million people in the United States had diabetes, projected to grow to 36.3 million by 2045. The rising number of diabetic cases is expected to increase the number of diabetic ulcer cases and contribute to market growth in the studied region.
Furthermore, as per the data published by BLS in 2021, private industry employers reported 2.6 million nonfatal workplace injuries and illnesses in 2021. Hence, as the number of injury cases increases the demand for enzymatic wound debridement products increases, thereby boosting the market growth over the forecast period. Moreover, product launches, conferences regarding the clinical outcome, acquisitions, and collaborations in the field of enzymatic wound debridement market are likely to boost the market growth over the forecast period. For instance, in April 2022, MediWound Ltd. presented a poster and oral presentation of its EscharEx clinical data at the 35th Symposium on Advanced Wound Care (SAWC) Spring Conference. EscharEx is an innovative enzymatic solution for the debridement of hard-to-heal wounds.
As a result of the increase in chronic wounds, the number of accidents, and technological advances in the products, the enzymatic wound debridement market in North America is expected to grow over the forecast period.
Get Analysis on Important Geographic Markets
Enzymatic Wound Debridement Industry Overview
The enzymatic wound debridement market is moderately competitive and consists of several major players. Some of the companies which are currently present in the market are B. Braun Melsungen AG, ConvaTec Inc., Smith & Nephew, Integra LifeSciences Corporation, and Mölnlycke Health Care AB among others.
Enzymatic Wound Debridement Market Leaders
B. Braun Melsungen AG
ConvaTec Inc.
Smith & Nephew
Integra LifeSciences Corporation
Mölnlycke Health Care AB
*Disclaimer: Major Players sorted in no particular order
Need More Details on Market Players and Competitors?
Enzymatic Wound Debridement Market News
- In October 2022, MediWound, released positive clinical data from the Company's EscharEx Phase 2 trials and were featured in an oral and two poster presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022 Conference. The data demonstrated EscharEx to be significantly better than gel vehicle and the non-surgical standard of care across multiple measures including the incidence of complete debridement, time to achieve complete debridement, and granulation tissue formation.
- In February 2022, Guild Biosciences received an FY19 Military Burn Research Program (MBRP) Idea Development Award to develop a nonsurgical burn wound debridement product suitable for use during prolonged field care.
Enzymatic Wound Debridement Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Chronic Wounds
4.2.2 Increasing Number of Accidents
4.2.3 Increasing Technologically Advanced Products
4.3 Market Restraints
4.3.1 Stringent regulatory policies
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - in USD Millions)
5.1 By Type
5.1.1 Chronic Wounds
5.1.2 Acute Wounds
5.2 By Product
5.2.1 Collagenase Product
5.2.2 Papain Product
5.2.3 Others
5.3 By End-User
5.3.1 Hospitals
5.3.2 Homecare
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 B. Braun Melsungen AG
6.1.2 ConvaTec Inc.
6.1.3 Smith & Nephew
6.1.4 Integra LifeSciences Corporation
6.1.5 Molnlycke Health Care AB
6.1.6 Healthpoint, Ltd
6.1.7 MediWound
6.1.8 3M Company
6.1.9 PAUL HARTMANN AG
6.1.10 Coloplast Corp
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Enzymatic Wound Debridement Industry Segmentation
As per the scope of the report, debridement is the procedure in which infected tissue is removed from the wound until the healthy tissue is exposed. Enzymatic debridement is the process of using exogenous enzymes to the surface of the wound so the degradation of necrotic tissue can occur without any negative effects on viable, granulation tissue. The Enzymatic Wound Debridement Market is Segmented by Type (Chronic Wounds, Acute Wounds), Product (Collagenase Product, Papain Product, and Others), End-User (Hospitals, Homecare, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends of 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type | |
| Chronic Wounds | |
| Acute Wounds |
| By Product | |
| Collagenase Product | |
| Papain Product | |
| Others |
| By End-User | |
| Hospitals | |
| Homecare | |
| Others |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Need A Different Region Or Segment?
Enzymatic Wound Debridement Market Research FAQs
What is the current Enzymatic Wound Debridement Market size?
The Enzymatic Wound Debridement Market is projected to register a CAGR of 5.30% during the forecast period (2024-2029)
Who are the key players in Enzymatic Wound Debridement Market?
B. Braun Melsungen AG, ConvaTec Inc., Smith & Nephew, Integra LifeSciences Corporation and Mölnlycke Health Care AB are the major companies operating in the Enzymatic Wound Debridement Market.
Which is the fastest growing region in Enzymatic Wound Debridement Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Enzymatic Wound Debridement Market?
In 2024, the North America accounts for the largest market share in Enzymatic Wound Debridement Market.
What years does this Enzymatic Wound Debridement Market cover?
The report covers the Enzymatic Wound Debridement Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Enzymatic Wound Debridement Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Enzymatic Wound Debridement Industry Report
Statistics for the 2023 Enzymatic Wound Debridement market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Enzymatic Wound Debridement analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
Enzymatic Wound Debridement Market Report Snapshots
